Document Detail

Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
MedLine Citation:
PMID:  22786687     Owner:  NLM     Status:  Publisher    
Edoxaban (the former DU176b) an orally available direct factor Xa inhibitor has been engineered from DX-9065a, which was one of the first parenteral Xa inhibitors. Edoxaban has a time to peak plasma concentrations of 1-2 hours and a half-life of approximately 10 hours after multiple doses. Edoxaban is the third new oral anticoagulant in the group of direct factor Xa inhibitors that has gained clinical approval for the prevention of venous thromboembolism after major orthopaedic surgery. Currently, edoxaban is assessed in late stage clinical development for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (ENGAGE AF-TIMI 48, NCT00781391) and for the treatment and prevention of venous thromboembolism in patients with acute deep vein thrombosis and/or pulmonary embolism (HOKUSAI VTE, NCT00986154). Both clinical phase III trials represent the largest single clinical studies in their entity so far with an enrolment of 21107 patients in ENGAGE AF-TIMI 48 and a planned enrolment of 7500 patients in HOKUSAI VTE. The pharmacological properties of edoxaban will be discussed along with the current late stage clinical development focusing on the prevention of stroke and venous thromboembolism.
I Ahrens; C Bode
Related Documents :
25228047 - Sirtuin 1 activity in peripheral blood mononuclear cells of patients with osteoporosis.
8527567 - Strongyloidiasis in patients with hematologic malignancies.
22633167 - Nilotinib-associated vascular events.
2512537 - Pathologic correlation of the unknown solid parotid mass in children.
16615687 - A statistical analysis of factors predisposing patients to heparin resistance.
6869657 - Assessment of the unstable shoulder by computed arthrography. a preliminary report.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-12
Journal Detail:
Title:  Hamostaseologie     Volume:  32     ISSN:  0720-9355     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8204531     Medline TA:  Hamostaseologie     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Ingo Ahrens, MD, Heart Center Freiburg University, Hugstetter Str. 55, 79106 Freiburg, Germany, E-mail:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Microarray comparative genomic hybridization and cytogenetic characterization of tissue-specific mos...
Next Document:  Direct Observation of Charge Transfer in Solid Electrolyte for Electrochemical Metallization Memory.